Abstract
ABSTRACTPurposeTo investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL).MethodsIn total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3–8 courses of chemotherapy. The expression of PD-L1 in tumor tissues from nine PTCL patients was also detected.ResultssPD-L1 was higher in PTCL patients at diagnosis compared to healthy subjects (P < 0.0001). Patients in the intermediate/high-risk disease group had a higher level of sPD-L1 than patients in the low-risk group (P = 0.0003). Elevated sPD-L1 (≥176.30 pg/ml) was the only biomarker for PTCL that retain statistical significance in multivariate analysis. Patients in the low-risk group with sPD-L1 ≥ 176.30 pg/ml had an adverse prognosis. Histological analysis showed that the expression of PD-L1 in tissues was positively correlated with sPD-L1 levels in plasma (Spearman = 0.9177, P = 0.0013).ConclusionssPD-L1 is a sensitive biomarker predicting clinical outcomes in PTCL.
Highlights
Peripheral T-cell lymphoma (PTCL) is a rare disease, comprising only 5–10% of all lymphoid neoplasms [1], but it shows a higher prevalence in China (23– 27%) [2]
We explored the clinical value of sPD-L1 in the plasma of patients with PTCL
High-sPD-L1 levels were the only significant risk factor for Overall survival (OS) and Progression-free survival (PFS) in multivariate analysis, which was consistent with several studies that showed high levels of sPD-L1 to be associated with poor prognosis in some malignancies [7,8,9]
Summary
Peripheral T-cell lymphoma (PTCL) is a rare disease, comprising only 5–10% of all lymphoid neoplasms [1], but it shows a higher prevalence in China (23– 27%) [2]. As a biologically and clinically heterogeneous group of diseases, PTCL remains a therapeutic challenge. The outcomes of conventional chemotherapy have been shown to be unsatisfactory, with 16–41% of patients experiencing disease relapse or progression [3,4]. A number of prognostic indexes have been developed for PTCL, including the International Prognostic Index (IPI), Prognostic Index for PTCL-U (PIT) and Prognostic Index of Natural Killer/ T (NK/T) Cell Lymphoma with Epstein–Barr virous DNA (PINK-E), these indexes rely predominantly on clinical parameters, and some patients with poor prognosis remain unidentified. Programmed death 1 (PD-1) protein is a key immune-checkpoint receptor. Increasing evidence has suggested that the level of soluble
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
